RETRACTED: Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class.
about
Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KITSelective inhibition of BET bromodomainsAnaplastic lymphoma kinase: signalling in development and diseaseLessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemiaModulation of the SH2 binding specificity and kinase activity of Src by tyrosine phosphorylation within its SH2 domainThe heterotopic tracheal allograft as an animal model of obliterative bronchiolitisSustained proliferation in cancer: Mechanisms and novel therapeutic targetsAcadesine kills chronic myelogenous leukemia (CML) cells through PKC-dependent induction of autophagic cell deathA current review of targeted therapeutics for ovarian cancer.Reversal of experimental pulmonary hypertension by PDGF inhibition.Development of inhibitors for protein tyrosine kinases.Recent advances in the molecular and cellular biology of chronic myeloid leukaemia: lessons to be learned from the laboratory.Modeling Philadelphia chromosome positive leukemias.Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase.The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies.BCR-ABL as a target for novel therapeutic interventions.Treatment of advanced dermatofibrosarcoma protuberans with imatinib mesylate with or without surgical resection.Occurrence of secondary malignancies in chronic myeloid leukemia during therapy with imatinib mesylate-single institution experience.Kaposi's sarcoma-associated herpesvirus-induced upregulation of the c-kit proto-oncogene, as identified by gene expression profiling, is essential for the transformation of endothelial cellsBlockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization.The cancer treatment revolutionSpecific inhibitors of platelet-derived growth factor or epidermal growth factor receptor tyrosine kinase reduce pulmonary fibrosis in rats.Tyrosine Kinase Inhibitors Regulate OPG through Inhibition of PDGFRβ.Evidence for a role of NF-kappaB in the survival of hematopoietic cells mediated by interleukin 3 and the oncogenic TEL/platelet-derived growth factor receptor beta fusion proteinTyrosine kinases in disease: overview of kinase inhibitors as therapeutic agents and current drugs in clinical trials.Knock-down of Kaiso induces proliferation and blocks granulocytic differentiation in blast crisis of chronic myeloid leukemiaTreatment with imatinib improves drug delivery and efficacy in NSCLC xenografts.Is phosphoproteomics ready for clinical research?Phase II trial of imatinib mesylate in patients with metastatic melanoma.Treatment for chronic myelogenous leukemia: the long road to imatinibProtein kinases as targets for cancer treatment.The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways.Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma.Imatinib mesilate for the treatment of gastrointestinal stromal tumour.Abl tyrosine kinases in T-cell signalingMolecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.Targeted therapies: the rare cancer paradigm.Imatinib relaxes the pulmonary venous bed of guinea pigs.Evolution of therapies for chronic myelogenous leukemia.Secondary malignancy after imatinib therapy: eight cases and review of the literature.
P2860
Q21142738-7AB7E245-0456-43CD-9D37-FD8E99484F77Q24301009-A5609098-A6FF-49B0-A27D-A568BEE6001BQ24312329-D8E137E6-1AA3-45E9-8309-7D29CCA7BEB8Q24599829-77B75C50-41F4-4E75-9642-27FBFD3A8C31Q28280523-88EB821D-B859-4277-A27F-F34FDB2E11E8Q28362902-41D43521-8CA3-4917-B87B-6DC5B9298FC7Q28396388-FF78B148-6AF3-4390-9D79-76115166AB87Q28471941-91222F38-9259-4926-829B-E251B3F025E0Q33580998-7C6DEC85-056A-4639-A650-99217602C6B6Q34048479-416950FA-4BD5-4BF9-81B0-4102354B1E75Q34103669-82477E33-9B65-4FE3-AD23-7AF55A16FA49Q34235845-9BA6464F-8B61-4648-A1AF-7F69B2BFB6F9Q34405446-9588A70F-2D26-43A5-A826-1B6B2402B373Q34443523-AF43F074-0DBF-4FC2-A01D-192CEA804635Q34471660-40712444-0EB2-4691-AF9A-CC24D0E1AAD7Q34568971-85CA9801-5D1D-4F25-84F3-95859DEB77D3Q34620856-2D2C0F15-BB65-4EB8-83F3-076EF4F84ADBQ34822070-CFCB32D0-B8F3-437E-A418-582DCA49FF65Q35000871-BEF5454C-7E2B-412E-8989-15AC91C9EE89Q35745444-A0E36DB5-D4FA-4AEE-B2E3-711E989A2749Q35778555-3D3048B0-B03C-43B2-8CB3-81BC7226B9D8Q35787237-38AC3E84-D567-4F9F-A22B-FC3DE5F64FC9Q36162943-F43F9BDB-2C80-4A0C-B6FA-5B707ADD3DE6Q36167190-9D739D84-7BF3-4353-86BE-4177AC86B2CDQ36181201-3E2A535E-8046-474D-BC98-6BA20FC41381Q36288848-BFD20918-C3A0-48C3-846C-DF97CCA88CEBQ36611170-708F4506-7868-4958-8624-EB84DFF9FA6CQ36799469-12DACD1C-2BDF-403E-A526-113A3C5E5153Q36859215-DBB78A7F-0ECB-450E-9030-ACC31DC9C8A9Q36900105-689BDD65-1441-4085-85E1-902E04C6C460Q36918131-0F6F3C2E-F144-4F93-96B3-9A2C845BD39AQ37054452-DE98779E-4441-4623-8B03-DF32C77F146EQ37109503-19214D5D-DD60-4748-AB53-3101BA63424DQ37142082-A047C02A-44B0-47D6-84F3-170F568D0775Q37182419-66275D89-C224-4839-89F2-4B76F20EF489Q37379320-BEB863E2-1CB3-4B58-9D2A-689240049DFAQ37632825-B14B3B4F-01F0-4D18-A8A0-8E288D3F6246Q37633669-D49A83B3-0D01-4FAB-8783-6617163A469EQ37966915-31BCA0FD-6EE9-48CA-9C81-E2336DE56D7BQ37983587-125A717B-E61E-4A4A-A522-B3BA6E4D4F86
P2860
RETRACTED: Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class.
description
1995 nî lūn-bûn
@nan
1995 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի մարտին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
RETRACTED: Selective inhibitio ...... 2-phenylaminopyrimidine class.
@ast
RETRACTED: Selective inhibitio ...... 2-phenylaminopyrimidine class.
@en
Selective inhibition of the pl ...... 2-phenylaminopyrimidine class.
@nl
type
label
RETRACTED: Selective inhibitio ...... 2-phenylaminopyrimidine class.
@ast
RETRACTED: Selective inhibitio ...... 2-phenylaminopyrimidine class.
@en
Selective inhibition of the pl ...... 2-phenylaminopyrimidine class.
@nl
altLabel
Selective inhibition of the pl ...... 2-phenylaminopyrimidine class
@en
prefLabel
RETRACTED: Selective inhibitio ...... 2-phenylaminopyrimidine class.
@ast
RETRACTED: Selective inhibitio ...... 2-phenylaminopyrimidine class.
@en
Selective inhibition of the pl ...... 2-phenylaminopyrimidine class.
@nl
P2093
P2860
P356
P1476
RETRACTED: Selective inhibitio ...... 2-phenylaminopyrimidine class.
@en
P2093
Buchdunger E
Regenass U
Zimmermann J
P2860
P304
P356
10.1073/PNAS.92.7.2558
P407
P577
1995-03-01T00:00:00Z